Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. Its product development programs focus primarily on important pharmaceutical markets with significant unmet medical needs and commercial potential. Its ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, around the clock blood levels of a dopamine agonist may benefit the patient and improve medical outcomes. The Company’s products are Probuphine and Fanapt (iloperidone). Its Probuphine is specifically designed for the long-term treatment of opioid dependence and utilizes ProNeura, proprietary, long-term drug delivery technology. The Company’s Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia.